AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24500145 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated intact parathyroid hormone (PTH) (>62 pg/mL) with very low calcium intake (<60% of EAR) or insufficient 25-hydroxyvitamin D (<20 ng/mL)
Number of subjects: 1116
Study 24500145 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calcium intake (<60% of EAR)
Number of subjects: 1116
Study 24500145 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low 25(OH)D (<12 ng/mL)
Number of subjects: 1116
Study 24500145 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated PTH (>62 pg/mL)
Number of subjects: 1116
Study 24500145 — intervention group
Group type: COMPARATOR
Intervention: Insufficient 25(OH)D or very low calcium intake without elevated PTH or with elevated PTH alone
Number of subjects: 1116
Study 24500148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt supplement (1.0 mg Co/d) for 90 days
Number of subjects: 10
Study 24500151 — intervention group
Group type: EXPERIMENTAL
Intervention: Equations developed using anthropometric and demographic variables for predicting 24EE.
Number of subjects: 481
Study 24500151 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined equations using energy expenditure values after 3 h and 7 h into the chamber study.
Number of subjects: 481
Study 24500152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) containing sodium selenite and antiretroviral drugs (ARV)
Number of subjects: 526
Study 24500152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LNS or ARV)
Number of subjects: 526
Study 24500155 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium intake >422.5 mg Mg/d
Number of subjects: 73684
Study 24500155 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium intake quintiles 4 and 5
Number of subjects: 73684
Study 24500940 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 stable magnesium isotopes (∼23 mg of oral ²⁶Mg and ∼11 mg of i.v. ²⁵Mg) administered to cohort 1
Number of subjects: 25
Study 24500940 — intervention group
Group type: EXPERIMENTAL
Intervention: Means of the 0-24 h urine and 3-h serum MgA values
Number of subjects: 25
Study 24500940 — intervention group
Group type: EXPERIMENTAL
Intervention: Means of the 0-24 h urine and 5-h serum MgA values
Number of subjects: 25
Study 24501009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804) 45 mg once daily continuously in 21-day cycles
Number of subjects: 66
Study 24501009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Number of subjects: 66
Study 24502477 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (DEB)
Number of subjects: 44
Study 24502477 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 44
Study 24502488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer Flow Modulator (MFM)
Number of subjects: 23
Study 24502534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular Botulinum toxin type A (BoNT-A) injection (100 units)
Number of subjects: 75
Study 24502534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronate injection plus rehabilitation exercise (30 minutes/day, 3 times/week for 4 weeks)
Number of subjects: 75
Study 24502534 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular hyaluronate injection plus rehabilitation exercise
Number of subjects: 75
Study 24502534 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular BoNT-A injection
Number of subjects: 75
Study 24502534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 75
Study 24502608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) optimization with echocardiography as reference
Number of subjects: 8
Study 24502608 — intervention group
Group type: COMPARATOR
Intervention: Shorter (<100 ms) or longer (>160 ms) AV settings
Number of subjects: 8
Study 24502608 — intervention group
Group type: COMPARATOR
Intervention: Ventricular (VV) optimization
Number of subjects: 8
Study 24502968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 751
Study 24503265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human recombinant interferon-beta-1a (FP-1201) at an optimal tolerated dose of 10 μg per day for 6 days
Number of subjects: 37
Study 24503265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study 24503265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human recombinant interferon-beta-1a (FP-1201)
Number of subjects: 37
Study 24504435 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 3 h/week vigorous activity
Number of subjects: 71
Study 24504435 — intervention group
Group type: COMPARATOR
Intervention: No vigorous activity
Number of subjects: 71
Study 24504442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 344
Study 24504509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced IgG antibodies to V1V2 regions of HIV-1 subtypes A, B, C, D, or CRF01_AE.
Number of subjects: 286
Study 24504509 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control).
Number of subjects: 286
Study 24504737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (low-dose)
Number of subjects: 6
Study 24506412 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast monotherapy (10 mg, once daily) in leukotriene-sensitive group
Number of subjects: 45
Study 24506412 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast monotherapy (10 mg, once daily) in leukotriene-insensitive group
Number of subjects: 45
Study 24506509 — intervention group
Group type: EXPERIMENTAL
Intervention: GMFCS level II
Number of subjects: 222
Study 24506509 — intervention group
Group type: EXPERIMENTAL
Intervention: GMFCS level III
Number of subjects: 222
Study 24506509 — intervention group
Group type: EXPERIMENTAL
Intervention: GMFCS level IV
Number of subjects: 222
Study 24506509 — intervention group
Group type: COMPARATOR
Intervention: Educational facilities
Number of subjects: 222
Study 24507585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive aerobic exercise and muscle endurance training (15 on the Borg RPE scale, 3 times/week for 8 weeks)
Number of subjects: 4
Study 24507865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with childhood craniopharyngioma and hypothalamic involvement
Number of subjects: 15
Study 24507865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with childhood craniopharyngioma and hypothalamic involvement (high-grade hypothalamic involvement)
Number of subjects: 15
Study 24507865 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 24507865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with childhood craniopharyngioma
Number of subjects: 15
Study 24508104 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on genomic alterations identified through CGH array and Sanger sequencing.
Number of subjects: 423
Study 24508104 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy received by 43 assessable patients.
Number of subjects: 423
Study 24508104 — intervention group
Group type: COMPARATOR
Intervention: Biopsy procedure.
Number of subjects: 423
Study 24508444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal transplantation of hUCB-derived MSCs (1 × 10(7) cells/kg for first 3 patients, 2 × 10(7) cells/kg for next 6 patients)
Number of subjects: 9
Study 24508444 — intervention group
Group type: COMPARATOR
Intervention: Historical case-matched comparison group
Number of subjects: 9
Study 24508509 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA (Neurally Adjusted Ventilator Assist)
Number of subjects: 10
Study 24508509 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV (Pressure-Support Ventilation)
Number of subjects: 10
Study 24508509 — intervention group
Group type: COMPARATOR
Intervention: NAVA
Number of subjects: 10
Study 24508509 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 10
Study 24508570 — intervention group
Group type: EXPERIMENTAL
Intervention: Permacol™ surgical implant
Number of subjects: 343
Study 24509907 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 110
Study 24510115 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients undergoing PCI
Number of subjects: 6218
Study 24510638 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT interruption for 1 month
Number of subjects: 4896
Study 24510638 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT interruption for >1-12 months
Number of subjects: 4896
Study 24510638 — intervention group
Group type: COMPARATOR
Intervention: No DAPT interruption
Number of subjects: 4896
Study 24510638 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT interruption for 1 month (long interruptions)
Number of subjects: 4896
Study 24510638 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT interruption for >1-12 months (long interruptions)
Number of subjects: 4896
Study 24510638 — intervention group
Group type: COMPARATOR
Intervention: Continuous DAPT
Number of subjects: 4896
Study 24512954 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 21-day cycle
Number of subjects: 20
Study 24513880 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) imaging by unenhanced computed X-ray tomography (CT)
Number of subjects: 300
Study 24513880 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC = 0
Number of subjects: 300
Study 24513880 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAC >400 Au
Number of subjects: 300
Study 24513880 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low pre-test probability of CAD and zero CAC
Number of subjects: 300
Study 24515353 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Buddies lesson plans
Number of subjects: 647
Study 24515353 — intervention group
Group type: COMPARATOR
Intervention: Regular curriculum
Number of subjects: 647
Study 24515598 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiogram-derived measures
Number of subjects: 21
Study 24515598 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiogram-derived measures in pure PAH phenotypes
Number of subjects: 21
Study 24515598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman analyses
Number of subjects: 21
Study 24516013 — intervention group
Group type: EXPERIMENTAL
Intervention: R (rituximab) 375 mg/m(2) once per week for 4 weeks
Number of subjects: 39
Study 24516013 — intervention group
Group type: EXPERIMENTAL
Intervention: R + MR (rituximab plus maintenance rituximab) administered once every 6 months for 2 years
Number of subjects: 39
Study 24516013 — intervention group
Group type: COMPARATOR
Intervention: R (rituximab)
Number of subjects: 39
Study 24516013 — intervention group
Group type: EXPERIMENTAL
Intervention: R + MR (rituximab plus maintenance rituximab)
Number of subjects: 39
Study 24516026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pegaspargase at 2,000 IU/m(2) per dose, administered in six doses with intervals longer than 4 weeks
Number of subjects: 51
Study 24516026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pegaspargase
Number of subjects: 51
Study 24517219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIG) therapy (0.4 g kg(-1) day(-1) for 5 days)
Number of subjects: 156
Study 24517388 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SAD during the Beliefs task
Number of subjects: 54
Study 24517388 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SAD during reappraising faces
Number of subjects: 54
Study 24517388 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SAD during reappraising criticism
Number of subjects: 54
Study 24517388 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SAD during reappraising beliefs
Number of subjects: 54
Study 24517388 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC) during the Beliefs task
Number of subjects: 54
Study 24517388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during the Faces and Criticism tasks
Number of subjects: 54
Study 24517388 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPFC activity in both groups
Number of subjects: 54
Study 24517417 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR birch pollen sublingual solution
Number of subjects: 574
Study 24517417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study 24517865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution anorectal manometry (HR-ARM)
Number of subjects: 26
Study 24517865 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard barostat
Number of subjects: 26
Study 24517865 — intervention group
Group type: EXPERIMENTAL
Intervention: RBB
Number of subjects: 26
Study 24517865 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-ARM
Number of subjects: 26
Study 24517865 — intervention group
Group type: COMPARATOR
Intervention: Elastic balloon measurements
Number of subjects: 26
Study 24519196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nanostructured formulation of progesterone (10%) combined with estriol (0.1%) + estradiol (0.25%)
Number of subjects: 66
Study 24519196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nanostructured formulation of progesterone and estrogens
Number of subjects: 66
Study 24519196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 66
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 1025
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 1025
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LSM (bLSM)
Number of subjects: 1025
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: bLSM <7 kPa
Number of subjects: 1025
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase (≥ 1 kPa/year) in 7-14 kPa bLSM
Number of subjects: 1025
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease (≤ 0 kPa/year) in ≥ 14 kPa bLSM
Number of subjects: 1025
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase (>0 kPa/year) in ≥ 14 kPa bLSM
Number of subjects: 1025
Study 24519328 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and delta FIB-4
Number of subjects: 1025
Study 24519427 — intervention group
Group type: EXPERIMENTAL
Intervention: PixR-NP cluster test (CT)
Number of subjects: 267
Study 24519427 — intervention group
Group type: EXPERIMENTAL
Intervention: PixR-NP single threshold test (STT)
Number of subjects: 267
Study 24519427 — intervention group
Group type: EXPERIMENTAL
Intervention: PixR-P single threshold test (STT)
Number of subjects: 267
Study 24519427 — intervention group
Group type: COMPARATOR
Intervention: statistic image mapping (SIM)
Number of subjects: 267
Study 24519964 — intervention group
Group type: EXPERIMENTAL
Intervention: PROgmatic trial management system
Number of subjects: 0
Study 24520093 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 peptide vaccine combined with Poly-ICLC (Hiltonol), granulocyte macrophage colony-stimulating factor (GM-CSF) ± montanide
Number of subjects: 27
Study 24520094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing GD2 and GD3 (30 μg each) and OPT-821 (150 μg/m²) with β-glucan (40 mg/kg/day, 14 days on/14 days off)
Number of subjects: 15
Study 24520446 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 80
Study 24520446 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 80
Study 24520818 — intervention group
Group type: EXPERIMENTAL
Intervention: MeTree (patient facing family history assessment tool)
Number of subjects: 1184
Study 24520818 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking with family members before using MeTree
Number of subjects: 1184
Study 24521776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/d)
Number of subjects: 12
Study 24521776 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (80 mg/d)
Number of subjects: 12
Study 24522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried food consumption
Number of subjects: 74
Study 24522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat intake
Number of subjects: 74
Study 24522441 — intervention group
Group type: EXPERIMENTAL
Intervention: >35% of daily energy intake from fat
Number of subjects: 74
Study 24522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Available carbohydrate intake
Number of subjects: 74
Study 24522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumption of soda
Number of subjects: 74
Study 24522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fiber intake
Number of subjects: 74
Study 24522445 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris-Benedict equation, Mifflin-St Jeor equation, Owen equation, and 6 questions from the revised ALS Functional Rating Scale (ALSFRS-R)
Number of subjects: 80
Study 24522445 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based calculator using the Rosenbaum equation and the same 6 questions from the ALSFRS-R
Number of subjects: 80
Study 24522446 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% linoleic acid (LA) emulsion
Number of subjects: 59
Study 24522446 — intervention group
Group type: COMPARATOR
Intervention: Control emulsion
Number of subjects: 59
Study 24522447 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids intake
Number of subjects: 52
Study 24522447 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs) intake
Number of subjects: 52
Study 24522447 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugar intake
Number of subjects: 52
Study 24523212 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenodiagnosis using Ixodes scapularis larvae
Number of subjects: 36
Study 24523212 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenodiagnosis
Number of subjects: 36
Study 24523241 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months)
Number of subjects: 3
Study 24523241 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months) in combination with imiquimod
Number of subjects: 3
Study 24523869 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving performance assessment using a dual-brake vehicle during a 40-minute driving task.
Number of subjects: 30
Study 24523869 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual exploration ability assessed through eye movements recorded by a mobile eye tracker.
Number of subjects: 30
Study 24523869 — intervention group
Group type: EXPERIMENTAL
Intervention: Head movements assessment in relation to driving test outcomes.
Number of subjects: 30
Study 24524285 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction program including daily caloric restriction and exercise for 12 weeks
Number of subjects: 36
Study 24524452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment for neonatal hypoxic-ischemic encephalopathy
Number of subjects: 0
Study 24524452 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24524662 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers associated with the research site in the Northwest
Number of subjects: 433
Study 24524662 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed caregivers
Number of subjects: 433
Study 24524662 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing physical quality of life
Number of subjects: 433
Study 24524662 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger female caregivers
Number of subjects: 433
Study 24524773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheilectomy
Number of subjects: 8
Study 24525446 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline/corticosteroid combination therapy
Number of subjects: 0
Study 24525446 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24525449 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index 0-2
Number of subjects: 191
Study 24525449 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index 3-4
Number of subjects: 191
Study 24525449 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index 5-6
Number of subjects: 191
Study 24525449 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index 7-10
Number of subjects: 191
Study 24525449 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 191
Study 24525449 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index
Number of subjects: 191
Study 24525531 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic telephonic assessment (ATA) system
Number of subjects: 444
Study 24526575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus irinotecan (1.3 mg/m² days 1, 4, 8, 11; 125 mg/m² days 1, 8 every 21 days)
Number of subjects: 41
Study 24526575 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone (as second line therapy)
Number of subjects: 41
Study 24527254 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis (PEP) with tenofovir/emtricitabine (Truvada)
Number of subjects: 53
Study 24527254 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) behavioral intervention targeting reductions in methamphetamine use
Number of subjects: 53
Study 24527713 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with 25OHD status of 20 ng/mL or greater
Number of subjects: 1824
Study 24527713 — intervention group
Group type: COMPARATOR
Intervention: Subjects with plasma 25OHD less than 20 nmol/L
Number of subjects: 1824
Study 24527713 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese subjects with 25OHD status of 20 ng/mL or greater
Number of subjects: 1824
Study 24527713 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight subjects with 25OHD status of 20 ng/mL or greater
Number of subjects: 1824
Study 24527713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-replete population
Number of subjects: 1824
Study 24527718 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 77